COGT - NOTRELOAD AI

COGT/ 03/16/2026 · 10:14 AM

Jefferies Slaps Buy Rating on Cogent Biosciences as FDA Accepts Bezuclastinib NDA for Non-Advanced Systemic Mastocytosis

Jefferies analyst started coverage on Cogent Biosciences with a Buy rating and $55 price target after the FDA accepted the NDA for bezuclastinib in Non-Advanced Systemic Mastocytosis. PDUFA date set for December 30, 2026.

Featured/ COGT/ 11/10/2025 · 10:00 AM

Historic Breakthrough in GIST Treatment: Cogent’s Bezuclastinib Combination Poised to Become New Standard of Care

Cogent Biosciences announced "transformative" success with their experimental drug, bezuclastinib, in combination with sunitinib, significantly delaying disease progression in patients battling advanced GIST (a form of stomach cancer).

COGT/ 10/20/2025 · 9:23 AM

Cogent Biosciences Receives FDA Breakthrough Designation for Mastocytosis Treatment

Cogent Biosciences announces FDA Breakthrough Therapy Designation for bezuclastinib, a promising treatment for NonAdvanced Systemic Mastocytosis with NDA submission planned by year-end 2025.

#COGT↓

Jefferies Slaps Buy Rating on Cogent Biosciences as FDA Accepts Bezuclastinib NDA for Non-Advanced Systemic Mastocytosis

Historic Breakthrough in GIST Treatment: Cogent’s Bezuclastinib Combination Poised to Become New Standard of Care

Cogent Biosciences Receives FDA Breakthrough Designation for Mastocytosis Treatment